磁共振成像病灶被分类为不确定、可能或高度可能为临床显著前列腺癌的男性的靶向活检结果
该研究回顾性纳入1057例接受MRI引导下活检的患者,病灶PI-RADS≥3。PI-RADS 3、4、5病灶的前列腺癌检出率分别为35%、60%、91%,临床显著前列腺癌检出率分别为17%、34%、67%。研究结论认为MRI引导下活检在既往活检阴性病例中临床显著前列腺癌检出率高。
要点
- PI-RADS 3、4、5病灶临床显著前列腺癌检出率分别为17%、34%、67%。
- 活检阴性患者中位随访41个月后临床显著前列腺癌检出率为1.7%。
- 若采用PSAD≥0.15ng/ml/ml阈值,42%的PI-RADS 3患者可避免活检,但6%的临床显著前列腺癌会被漏诊。
核心结论
- 在既往活检阴性的病例中,对PI-RADS≥3病灶行MRI引导下活检在每日临床实践中可获得较高的临床显著前列腺癌检出率。
研究设计与样本
- 回顾性纳入2012年1月至2016年9月期间接受MRI引导下活检的1057例患者,病灶在多参数MRI上分类为PI-RADS≥3。
- 纳入初诊活检患者、既往经直肠超声引导系统活检阴性患者以及主动监测患者。
主要发现
- PI-RADS 3、4、5病灶的前列腺癌检出率分别为35%(55/156)、60%(223/373)、91%(479/528)。
- PI-RADS 3、4、5病灶的临床显著前列腺癌检出率分别为17%(26/156)、34%(128/373)、67%(352/528)。
- 活检阴性患者中位随访41个月(四分位距25-50个月)后,临床显著前列腺癌检出率为1.7%(5/300)。
- 采用PSAD≥0.15ng/ml/ml预测临床显著前列腺癌时,42%的PI-RADS 3病灶患者可避免活检,但6%(95%CI 2-15)的临床显著前列腺癌会被漏诊。
关键数值与推荐
- 临床显著前列腺癌定义为Gleason评分≥3+4。
- PI-RADS 3、4、5病灶的临床显著前列腺癌检出率分别为17%(26/156)、34%(128/373)、67%(352/528)。
- PSAD≥0.15ng/ml/ml阈值下,42%的PI-RADS 3病灶患者可避免活检,6%(95%CI 2-15)的临床显著前列腺癌会被漏诊。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究为回顾性性质。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Prostate Imaging Reporting and Data System (PI-RADS) is the most commonly used scoring system in prostate magnetic resonance imaging (MRI). One of the available techniques to target suspicious lesions is direct in-bore MRI-guided biopsy (MRGB). OBJECTIVE: To report on the experience and results of MRGB in a large cohort of patients with lesions classified as equivocal (PI-RADS 3), likely (PI-RADS 4), or highly likely (PI-RADS 5) to be clinically significant (cs) prostate cancer (PCa). DESIGN, SETTING, AND PARTICIPANTS: We retrospectively included 1057 patients having MRGB, between January 2012 and September 2016, of lesions classified as PI-RADS≥3 on multiparametric MRI. Biopsy-naïve patients, patients with prior negative systematic transrectal ultrasound-guided biopsy, and patients in active surveillance were included. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome measurement is the detection rate of csPCa. Descriptive statistics and chi-square tests were used to calculate the differences in proportions. We considered a Gleason score of ≥3+4 as csPCa. RESULTS AND LIMITATIONS: PCa was diagnosed in 35% (55/156), 60% (223/373), and 91% (479/528), and csPCa in 17% (26/156), 34% (128/373), and 67% (352/528) of patients with PI-RADS 3, 4, and 5 lesions, respectively. Follow-up of patients with negative biopsy findings resulted in csPCa in 1.7% (5/300) after a median period of 41 (interquartile range 25-50) mo. The evaluation of prostate-specific antigen density (PSAD) to predict csPCa resulted in 42% of patients with a PI-RADS 3 lesion who could avoid biopsy in case a PSAD of ≥ 0.15ng/ml/ml would be used. In 6% (95% confidence interval, 2-15), csPCa would then be missed. The study is limited because of its retrospective character. CONCLUSIONS: MRGB in lesions scored PI-RADS≥3 yields high detection rates of csPCa in daily clinical practice in cases with previous negative biopsy. PATIENT SUMMARY: In daily clinical practice, direct in-bore magnetic resonance imaging-guided biopsy of suspicious lesions reported according to the Prostate Imaging Reporting and Data System yields high detection rates of clinically significant prostate cancer.
引用
- Venderink W, van Luijtelaar A, Bomers JGR, et al. Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate Cancer. Eur Urol. 2017. PMID: 28258784. doi:10.1016/j.eururo.2017.02.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。